Gastric polyp Medical Services in China

Gastric polyps are localized, benign mucosal protrusions arising from the stomach lining. They are typically discovered incidentally during upper gastrointestinal endoscopy performed for unrelated symptoms such as dyspepsia, anemia, or surveillance. While most gastric polyps are asymptomatic and non-neoplastic, their clinical significance lies in their heterogeneous histopathology—primarily classified as hyperplastic polyps (60–80%), fundic gland polyps (10–30%), and adenomatous polyps (<10%). Adenomatous polyps carry the highest malignant potential, with risk of progression to gastric adenocarcinoma increasing with size (>2 cm), dysplasia grade, and presence of intestinal metaplasia. Pathogenesis varies by type: hyperplastic polyps are strongly associated with chronic atrophic gastritis and Helicobacter pylori infection, leading to mucosal injury and regenerative hyperplasia; fundic gland polyps are often linked to long-term proton pump inhibitor (PPI) use or familial adenomatous polyposis (FAP); adenomatous polyps arise from neoplastic transformation of gastric epithelium, frequently in the context of chronic inflammation, bile reflux, or genetic predisposition. Epidemiologically, gastric polyps are detected in 1–6% of routine upper endoscopies in adults, with prevalence rising sharply after age 50. Hyperplastic polyps predominate in older women and individuals with H. pylori-related gastritis, while fundic gland polyps are more common in middle-aged women on chronic PPI therapy. Risk factors include persistent H. pylori infection, autoimmune gastritis, long-term PPI use (>1 year), smoking, high-salt diet, and genetic syndromes such as FAP or Lynch syndrome. Although most patients remain asymptomatic, larger or multiple polyps may cause occult gastrointestinal bleeding (leading to iron-deficiency anemia), epigastric discomfort, nausea, or, rarely, gastric outlet obstruction. Quality of life impact is generally low for small, non-dysplastic polyps under surveillance; however, patients face psychological burden from cancer anxiety, repeated endoscopic monitoring, dietary restrictions, and medication adjustments. Those requiring polypectomy or surgical resection experience short-term procedural recovery, potential complications (e.g., bleeding, perforation), and long-term surveillance obligations—impacting work productivity, travel, and healthcare engagement. Timely diagnosis via high-definition endoscopy with chromoendoscopy or narrow-band imaging, coupled with targeted biopsy and histopathologic classification, is essential to guide risk-stratified management and prevent unnecessary interventions or missed malignancy.

Gastric polyps are mucosal protrusions within the stomach lumen, typically discovered incidentally during upper gastrointestinal endoscopy. They represent a heterogeneous group of lesions with varying histopathological features, biological behaviors, and malignant potential. Accurate classification—primarily into hyperplastic polyps (most common, low malignant risk), fundic gland polyps (often associated with proton pump inhibitor use or familial adenomatous polyposis), and adenomatous polyps (premalignant, with documented progression to gastric adenocarcinoma)—is essential for guiding management. Treatment strategy is individualized based on polyp size, number, morphology, histology, patient age, comorbidities, and surveillance feasibility.

Conservative treatment is appropriate for small (<5 mm), asymptomatic, non-adenomatous polyps—particularly solitary hyperplastic or fundic gland polyps without dysplasia. In such cases, observation with scheduled endoscopic surveillance is preferred over intervention. Surveillance intervals depend on histology and risk profile: patients with sporadic hyperplastic polyps <10 mm and no dysplasia generally require repeat gastroscopy in 3–5 years; those with multiple (>20) or larger (>10 mm) hyperplastic polyps may warrant more frequent monitoring (every 1–2 years) due to slightly elevated neoplastic risk. Conservative management also includes addressing underlying drivers—such as eradicating Helicobacter pylori infection (a known contributor to chronic gastritis and hyperplastic polyp formation) and discontinuing long-term proton pump inhibitors when clinically feasible in patients with fundic gland polyps. Lifestyle modifications—including smoking cessation, moderation of alcohol intake, and dietary optimization (increased fruits/vegetables, reduced salted/preserved foods)—are recommended to mitigate chronic gastric inflammation and oxidative stress.

Pharmacologic therapy plays a supportive rather than definitive role. There are no FDA- or EMA-approved drugs specifically for gastric polyp regression. However, H. pylori eradication regimens (e.g., bismuth quadruple therapy or clarithromycin-based triple therapy, tailored per local antibiotic resistance patterns) significantly reduce recurrence of hyperplastic polyps and improve gastric mucosal health. In patients with autoimmune gastritis-associated fundic gland polyps, high-dose vitamin B12 supplementation may be indicated but does not affect polyp burden. For patients with familial adenomatous polyposis (FAP), chemoprevention with sulindac or celecoxib has shown modest reduction in duodenal polyp burden but lacks robust evidence for gastric efficacy and is not routinely recommended for isolated gastric polyps. Proton pump inhibitors remain first-line for symptom control in patients with concomitant GERD or erosive gastritis but should be used at the lowest effective dose and duration to avoid potential polyp proliferation.

Surgical treatment is rarely required for gastric polyps but becomes necessary in specific scenarios. Endoscopic resection is the primary therapeutic modality—not surgical gastrectomy—for most polyps ≥6 mm, all adenomatous polyps regardless of size, and any polyp exhibiting suspicious features (e.g., nodularity, ulceration, rapid growth, or surface irregularity). Techniques include cold snare polypectomy (for polyps <10 mm without dysplasia), hot snare polypectomy, endoscopic mucosal resection (EMR) for flat or laterally spreading lesions up to 20 mm, and endoscopic submucosal dissection (ESD) for larger (>20 mm), complex, or recurrent adenomas where en bloc resection and precise histopathologic assessment are critical. Surgical gastrectomy (subtotal or total) is reserved for rare cases: multifocal high-grade dysplasia unamenable to endoscopic clearance, invasive carcinoma confirmed in a polyp, or diffuse gastric polyposis with uncontrollable bleeding or obstruction. Laparoscopic-assisted or robotic-assisted resections are increasingly utilized in tertiary centers for select cases requiring surgical intervention, offering improved precision and faster recovery versus open surgery.

Treatment in China offers distinct advantages rooted in infrastructure, expertise, and integration. China hosts the world’s largest volume of upper GI endoscopies annually, fostering unparalleled operator experience—especially in advanced resection techniques like ESD. Major academic centers (e.g., Zhongshan Hospital Fudan University, Peking Union Medical College Hospital) maintain standardized national guidelines aligned with ACG and ESGE recommendations while incorporating real-world data from Chinese cohorts. Rapid adoption of AI-assisted endoscopic imaging (e.g., real-time histology prediction via narrow-band imaging + deep learning algorithms) enhances detection and characterization accuracy. Furthermore, China’s centralized pathology networks enable expedited, high-fidelity histologic interpretation with molecular subtyping (e.g., mismatch repair protein immunohistochemistry) when indicated. Cost-effectiveness is notable: endoscopic resection costs approximately 30–50% less than comparable procedures in Western Europe or North America, with minimal out-of-pocket expense under national health insurance for eligible indications. Multidisciplinary tumor boards integrating gastroenterologists, pathologists, oncologists, and surgeons ensure coordinated decision-making for high-risk cases.

Post-treatment recovery emphasizes safety, surveillance, and mucosal healing. Patients undergoing endoscopic resection should observe a clear-liquid diet for 6–12 hours post-procedure, advancing to soft bland foods over 2–3 days; NSAIDs and anticoagulants must be withheld per protocol (typically 5–7 days) unless bridging strategies are implemented. Vigilance for delayed complications—such as post-polypectomy bleeding (occurs in ~1–3% of EMR/ESD cases) or perforation (<0.5%)—is critical; symptoms including hematemesis, melena, or acute abdominal pain warrant immediate evaluation. Follow-up endoscopy is mandatory: for complete EMR/ESD specimens, a control exam at 3–6 months confirms clearance and assesses for residual or recurrent disease; thereafter, surveillance intervals are stratified by final histology (e.g., low-grade dysplasia: every 1–3 years; high-grade dysplasia: every 6–12 months until stable). Long-term gastric health maintenance includes annual serum pepsinogen I/II ratio and gastrin-17 testing in patients with atrophic gastritis or intestinal metaplasia, periodic H. pylori retesting if initially positive, and avoidance of chronic irritants (smoking, excessive alcohol, habitual NSAID use). Nutritional counseling focusing on antioxidant-rich foods and micronutrient sufficiency (vitamin C, selenium, folate) supports epithelial integrity and reduces oxidative DNA damage. Psychological support is encouraged, particularly for patients with FAP or high-grade dysplasia, to address anxiety related to cancer risk and surveillance burden.